AIM ImmunoTech Inc. (AIM)

NYSE American - Nasdaq Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

0.9900

+0.0500

(+5.32%)

At close: 04:00PM EDT

0.9702

+0.01

(+0.74%)

After hours:

04:03PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Double Moving Average Crossover

View all chart patterns

Performance Outlook

Previous Close	0.9400
Open	0.9776
Bid	0.9701 x 1200
Ask	0.9999 x 39400
Day's Range	0.9601 - 1.0500
52 Week Range	0.5500 - 2.4000
Volume	431,389
Avg. Volume	543,193

Market Cap	47.568M
Beta (5Y Monthly)	-0.59
PE Ratio (TTM)	N/A
EPS (TTM)	-0.4040
Earnings Date	Aug 10, 2022 - Aug 15, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	5.83

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AIM

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

AIM ImmunoTech Inc.
Analyst Report: Merck & Co IncMerck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.
Rating
Fair Value
Economic Moat
2 days agoArgus Research

All

GlobeNewswire
AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference
OCALA, Fla., May 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer of AIM, will present at the H.C. Wainwright Global Investment Conference being held May 23-26,
- Nemaura Medical to Present at the H.C. Wainwright Global Hybrid Investment Conference
  GlobeNewswire
- Energy Focus to Participate at the H.C. Wainwright Global Investment Conference on May 23-26, 2022
  Business Wire
GlobeNewswire
AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program
AIM Chief Medical Officer David Strayer, MD AIM Chief Medical Officer David Strayer, MD Charles Lapp, MD, Principal Investigator for AMP-511 at Hunter-Hopkins Center in Charlotte, N.C. Charles Lapp, MD, Principal Investigator for AMP-511 at Hunter-Hopkins Center in Charlotte, N.C. Oved Amitay, President and CEO of the advocacy organization Solve M.E. Oved Amitay, President and CEO of the advocacy organization Solve M.E. AIM CEO Thomas K. Equels AIM CEO Thomas K. Equels OCALA, Fla., May 18, 2022
GlobeNewswire
AIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update
- First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage pancreatic cancer; results also showcased continued positive data in ovarian and triple-negative breast cancer clinical studies as well as clinical potential with checkpoint inhibitors - On track to commence Phase 2 study for lead program of Ampligen for pancreatic cancer Q3 2022 - Focus on further advancement of oncology pipeline and well-positio